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Invasive lobular breast cancer (ILC) is an understudied malignancy with distinct clinical, pathological,
and molecular features that distinguish it from the more common invasive ductal carcinoma (IDC).
Mounting evidence suggests that estrogen receptor-alpha positive (ERþ) ILC has a poor response to
Tamoxifen (TAM), but the mechanistic drivers of this are undeﬁned. In the current work, we compre-
hensively characterize the SUM44/LCCTam ILC cell model system through integrated analysis of gene
expression, copy number, and mutation, with the goal of identifying actionable alterations relevant to
clinical ILC that can be co-targeted along with ER to improve treatment outcomes. We show that TAM has
several distinct effects on the transcriptome of LCCTam cells, that this resistant cell model has acquired
copy number alterations and mutations that impinge on MAPK and metabotropic glutamate receptor
(GRM/mGluR) signaling networks, and that pharmacological inhibition of either improves or restores the
growth-inhibitory actions of endocrine therapy.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Invasive lobular breast cancer (ILC) is a special histologic sub-
type of breast cancer that accounts for 10e15% of annually diag-
nosed cases e an identical percentage to triple negative breast
cancer. ILC has unique clinical features that distinguish it from the
more common invasive ductal breast cancer (IDC) (Barroso-Sousa
and Metzger-Filho, 2016; Christgen et al., 2016; Sledge et al.,
2016) e it forms a long, thin mass that is often missed by screening
mammograms, and metastatic ILC frequently spreads to distinct
sites (e.g. peritoneum, gastrointestinal tract, orbital cavity) that12 Research Bldg., Washing-
R.B. Riggins).
Ireland Ltd. This is an open accessdiffer from IDC. This unique biology of ILC impacts disease prog-
nosis. ILC has a greater risk of late recurrence and death (>10 years
post-diagnosis) than IDC (Pestalozzi et al., 2008; Rakha et al., 2008).
Grade 2 (moderately differentiated) ILC has an equally poor breast
cancer-speciﬁc survival to grade 3 (poorly differentiated) IDC
(Engstrøm et al., 2015). The most common genetic lesion in ILC is
mutation of CDH1 leading to loss of E-cadherin expression, which is
thought to underlie ILC's unusual metastatic pattern as well as its
tendency to bemultifocal and affect the contralateral breast. Recent
studies have performed genomic, transcriptomic, and proteomic
characterization of ILC clinical specimens to identify additional
events that are enriched in ILC vs. IDC; these include higher rates of
PTEN loss, FOXA1mutation, and AKT phosphorylation (Ciriello et al.,
2015; Desmedt et al., 2016; Michaut et al., 2016).
Molecular proﬁling of breast cancer classiﬁes most ILC as
Luminal A e estrogen receptor positive (ERþ), and slow-growing earticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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(TAM) or an aromatase inhibitor (AI) is recommended (Azim et al.,
2016; Rugo et al., 2016). Within ILC, there are 2e3 additional mo-
lecular subtypes (Ciriello et al., 2015; Michaut et al., 2016). Among
ER þ or Luminal A breast tumors, lobular histology is still inde-
pendently and signiﬁcantly associated with worse long-term sur-
vival outcome than ductal histology (Pestalozzi et al., 2008; Rakha
et al., 2008), and multiple studies show that ER þ ILC has a
signiﬁcantly worse response to TAM than the non-steroidal AIs
letrozole or anastrozole (Knauer et al., 2015; Metzger Filho et al.,
2015). ILC patients also have inferior overall survival on the ste-
roidal AI exemestane vs. anastrozole, while in IDC they have
equivalent efﬁcacy (Strasser-Weippl et al., 2016).
ILC is an understudied malignancy and thus the reasons for its
relatively poor response toTAM are notwell deﬁned.We previously
established the ﬁrst cellular model of TAM-resistant ILC (Riggins
et al., 2008); SUM44 cells are the parental, TAM sensitive cell line
while LCCTam cells are TAM-resistant. These initial studies identi-
ﬁed an orphan member of the nuclear receptor superfamily,
estrogen-related receptor gamma (ERRg, ESRRG), as a key mediator
of the TAM-resistant phenotype. In the current work, we compre-
hensively characterize this ILC model system through integrated
analysis of genome-wide gene expression, copy number, and whole
exome sequencing (WES), with the goal of identifying actionable
alterations relevant to clinical ILC that can be targeted to improve
therapeutic outcomes. We ﬁnd that 4-hydroxytamoxifen (4HT) has
a distinct effect on the transcriptome of LCCTam cells, that this
resistant cell model has acquired copy number alterations and
speciﬁc gene mutations that impinge on MAPK and metabotropic
glutamate receptor (GRM/mGluR) signaling networks, and that
pharmacological inhibition of either improves or restores the
growth-inhibitory actions of endocrine therapy.
2. Materials and methods
2.1. General study design
We have previously reported the establishment and initial
validation of a TAM-resistant ILC cell line (LCCTam) established
from the parental SUM44 (Riggins et al., 2008). Here, we demon-
strate the utility of this model system for studying TAM-resistant
ILC by comparing SUM44 with publicly available breast cancer
patient datasets. Subsequent comprehensive molecular analysis of
LCCTam cells was performed in comparison to SUM44 cells utilizing
gene expression array, Whole Exome Sequencing (WES), and Array
Comparative Genomic Hybridization (aCGH). Selected molecular
targets from this analysis were validated and functional analyses
were performed using drugs of interest that resensitize TAM-
resistant cells to endocrine therapy as measured by growth
inhibition.
2.2. TCGA and METABRIC datasets, and tumor-derived ILC signature
(TIS)
cBioPortal (Cerami et al., 2012; Gao et al., 2013) was used to
query processed gene expression microarray, whole-exome, and
RNA sequencing data for Luminal A IDC and Luminal A ILC tumors
from The Cancer Genome Atlas (TCGA, (Ciriello et al., 2015)) and the
Molecular Taxonomy of Breast Cancer International Consortium
(METABRIC, (Curtis et al., 2012; Pereira et al., 2016)). To establish
the tumor-derived ILC signature (TIS, Fig. 1A), RNA-seq data for
Luminal A ILC (n ¼ 106) and IDC (n ¼ 201) were downloaded from
the TCGA Portal (http://cbio.mskcc.org/cancergenomics/tcga/brca_
tcga/). The differentially expressed genes between these two his-
tologic subtypes were identiﬁed using the‘ComparativeMarkerSelection’ module from GenePattern (Reich
et al., 2006), and plotted by alignment of their tested t-score after
permutation. The top 100 genes including both directions (2  50)
were deﬁned as a ‘tumor-derived ILC gene signature’ (TIS) for the
comparison of signature proﬁles among different cell models, using
a t-score method as described previously (Creighton et al., 2010).
Supplementary Table 1 shows sample identiﬁers for TCGA and
METABRIC datasets. Distant metastasis-free survival (DMFS) data
for GRM2 and GRM4 mRNA expression by Affymetrix gene
expression microarray in ERþ, TAM-treated, chemotherapy-naïve
patients were obtained from multiple combined datasets as
described previously (Mihaly et al., 2013) (Supplementary Fig. 2).
The ﬁnal database included patients from GSE2990, GSE3494,
GSE6532, GSE12093, GSE9195, GSE16391, GSE17705, GSE19615,
GSE26971, and GSE45255.2.3. Cell culture and general reagents
The ILC-derived, ER þ parental SUM44 breast cancer cells were
initially characterized by (Ethier et al., 1993), and the ERþ, TAM-
resistant variant LCCTam were ﬁrst reported in (Riggins et al.,
2008). SUM44 cells were maintained in serum-free Ham's F12
media (Life Technologies, Carlsbad, CA; 100 nM glutamate) con-
taining 5 mg/ml insulin and 1 mg/ml hydrocortisone (SFIH) plus
other supplements as follows: 5 mM ethanolamine, 10 mM HEPES,
5 mg/ml Transferrin, 10 nM Tri-iodo thyronine, 50 mM sodium
selenite, 0.5 g/L bovine serum albumin, 2.5 mg/ml amphotericin B,
and 5 mg/ml gentamicin (all purchased from either Life Technolo-
gies or Sigma Aldrich, St. Louis, MO). LCCTam cells were maintained
in SFIH with the addition of 500 nM 4HT (Sigma Aldrich), and
switched to SFIH lacking 4HT as indicated below. The IDC-derived,
ER- MDA-MB-231 cell line was obtained from the Lombardi
Comprehensive Cancer Center (LCCC) Tissue Culture Shared
Resource (TCSR), and was maintained in phenol red-containing
improved minimal essential media (IMEM) supplemented with
5% heat-inactivated fetal bovine serum (FBS). All cells routinely
tested negative for Mycoplasma spp., and were maintained in a
37 C, humidiﬁed incubator with 95% air: 5% carbon dioxide. Cells
were ﬁngerprinted by the TCSR to verify their authenticity using 9
standard short tandem repeat (STR) loci and the Y chromosome-
speciﬁc amelogenin, most recently in October 2016. Fulvestrant
(ICI), Riluzole (RIL), and U0126 were purchased from Tocris
Bioscience (RNDSystems, Minneapolis, MN) and used at the indi-
cated concentrations. Unless otherwise speciﬁed, general labora-
tory chemicals were obtained from Sigma Aldrich.2.4. Gene expression
Gene expression microarray data for parental SUM44 breast
cancer cells, and the resistant variant LCCTam maintained in the
presence of 500 nM 4HT, have been previously published and
deposited with Gene Expression Omnibus (GEO; GSE12708,
(Riggins et al., 2008)). Total RNA was isolated from SUM44 cells
treated with 500 nM 4HT for 24 h, or LCCTam cells cultured in the
absence of 4HT for 14 days, using TRIzol (ThermoFisher, Waltham,
MA) and the RNEasy Mini Kit (Qiagen, Germantown, MD). Total
RNA was labeled and processed for hybridization to Affymetrix
U133A GeneChips as described previously (Gomez et al., 2007;
Riggins et al., 2008). These data are available through GEO acces-
sion number GSE96570, and together as SuperSeries GSE96670.
Raw data for these and our previously published data (GSE12708,
(Riggins et al., 2008)) were preprocessed together using the Robust
Multiple-Array Average (RMA) method (Irizarry et al., 2003) using
Bioconductor.
Fig. 1. Expression of ESRRG and receptor target genes in Luminal A ILC. A, Tumor-derived ILC Signature (TIS) comprises top discriminant genes (50 up, 50 down) differentially
expressed between Luminal A ILC and Luminal A IDC in the TCGA dataset from (Ciriello et al., 2015). Down-regulated genes in ILC vs. IDC include CDH1 and PTEN, which are mutated
and deleted in ILC respectively. B, ESRRG mRNA expression is signiﬁcantly higher in Luminal A ILC vs. Luminal A IDC in the combined METABRIC dataset in cBioPortal. Gene
expression microarray data were compared by Mann-Whitney U test. C and D, mRNA expression of a four-gene ESRRG target signature is associated with poor outcome in Luminal A
ILCs from TCGA (C) and METABRIC (D). mRNA levels are as measured by RNAseq (TCGA) or gene expression microarray (METABRIC), and high or low expression corresponds to
above or below the median, respectively. Log-rank values calculated by cBioPortal.
H. Stires et al. / Molecular and Cellular Endocrinology 471 (2018) 105e117 1072.5. Array comparative genomic hybridization (aCGH)
Genomic DNA was isolated from SUM44 and LCCTam cells, the
latter cultured in the absence of 4HT for 14 days, using the illustra
triplePrep kit (GE Healthcare, Buckinghamshire, UK) according to
manufacturer's instructions. DNA copy number analysis was per-
formed using an oligonucleotide array-CGH platform (SurePrint G3
Human CGH Microarray 8  60 K; Agilent Technologies Inc., Santa
Clara, CA), as published previously (Torresan et al., 2014). DNA
isolated from peripheral blood from multiple normal individuals
was used as reference DNA. Brieﬂy, equal amounts of cell line and
reference DNAwere directly labeledwith Cy3 and Cy5, respectively,
using the SureTag Labeling Kit (Agilent Technologies) and hybrid-
ized in the presence of human Cot1-DNA (Life Technologies) to the
array for 40 h. The arraywas scanned using an Agilent array scanner
and data was extracted using Feature Extraction (FE) software
v10.10. For data analysis we used two different global analysis
methods: Aberration Detection Module-2 (ADM-2, Agilent Tech-
nologies) and Circular Binary Segmentation (CBS). Raw data can be
found at https://doi.org/10.17605/OSF.IO/7X8NG.
ADM-2. Data were analyzed using the Genome Workbenchversion 7.0 software (Agilent Technologies). For each sample, FE
gave a log10 ratio (log of sample processed signal over reference
processed signal for each gene) that was imported into Genome
Workbench and transformed and viewed as a log2-based ratio.
Outliers detected by the FE were excluded from the analysis. The
algorithm ADM-2 and a threshold value of 6.0 were applied with an
aberration ﬁlter with a minimum number of 3 consecutive probes.
Gene ampliﬁcations and deletions were considered when the cor-
responding plotted oligo-probes presented values of log2 ratio in-
tensity of the Cy5 dye (reference DNA)/intensity of the Cy3 dye (test
DNA) > 7/6 and log2 <5/6, respectively.
CBS. To calculate log2(copy number ratio) for each probe, we
considered only probes that had ControlType equal to '0'. We took
the log2 of the ratio of the green to red signal after correction
(gProcessedSignal/rProcessedSignal) for each probe. Segmentation
analysis for the aCGH copy number log-ratio was then performed
through the use of the Circular Binary Segmentation (CBS) Algo-
rithm, as implemented in the DNAcopy package in R version 3.1.2
(Olshen et al., 2004; Venkatraman and Olshen, 2007). Default
values for all parameters were used, except that consecutive seg-
ments were merged using the undo.splits ¼ “sdundo” option with
Table 1
qRTPCR primers.
Gene Forward Reverse
NF1 GAAGTAGGCAGCTGACAGAAA TCAACCACCATGGACTGAAC
MAPK1 TCCCAAATGCTGACTCCAAA TCGTCACTCGGGTCGTAATA
FOXA1 GGGGGTTTGTCTGGCATAGC GCACTGGGGGAAAGGTTGTG
GRM2 AACTTCAACGAGGCCAAG TCACTGGAGGTGACATAGAA
ACTB GAGCACAGAGCCTCGCCTTT TCATCATCCATGGTGAGCTGG
TUBB ATTCCAACCTTCCAGCCTGC CCAGAACTTGGCACCGATCT
H. Stires et al. / Molecular and Cellular Endocrinology 471 (2018) 105e117108the undo.SD parameter set to 0.3/DLRS, where DLRS (derivative log
ratio spread) represents the local SD in log ratio units, awell-known
measure of local variability for aCGH microarrays. In this way, the
segmentation algorithmwas tuned to detect copy number changes
of at least 0.3 in magnitude on the log2 scale. Segments were re-
ported as ampliﬁed or deleted if the corresponding estimated copy
number ratio was greater than 1.3 or less than 0.7, respectively.
Copy-number plots were created in R showing the log2 green:red
ratios as colored points and the CBS-generated segments as black
lines; any segments falling outside the plot range are indicated as
labeled black points.
2.6. Whole-exome sequencing (WES)
Genomic DNA was isolated from SUM44 and LCCTam cells, the
latter cultured in the absence of 4HT for 14 days, using the DNeasy
Mini kit (Qiagen). Exome enrichment was performed using the
Illumina TruSeq Exome Library Prep Kit (San Diego, CA), then
sequenced on an Illumina HiScanQ instrument at Children's Na-
tional Medical Center. Paired-end sequencing reads were obtained
for all samples. NGS reads were mapped to the hg19 human
reference genome using BWA-MEM (Li and Durbin, 2009), dupli-
cate reads were removed using Picard (unpublished, http://
broadinstitute.github.io/picard/), local realignments were per-
formed using GATK (McKenna et al., 2010), and .bam ﬁles of bio-
logical replicates were merged using SAMtools (Li et al., 2009) to
increase the total coverage. The variants were called using Atlas2
Suite (Challis et al., 2012). A population frequency threshold of 1%
was used to ﬁlter out common variants. Four next-generation
sequencing (NGS) cohort databases were used to determine allele
frequencies in population, including 1000 Genome Project
(Abecasis et al., 2012), Human Genetic Variation Database (Higasa
et al., 2016), Exome Aggregation Consortium (Lek et al., 2016) and
CHARGE cohort (Psaty et al., 2009). After the frequency-based
ﬁltering step, the putative functional consequences of remaining
rare variants were annotated using ANNOVAR (Wang et al., 2010).
The synonymous variants were further ﬁltered out and dbNSFP (Liu
et al., 2013) was used to compile in silico predictions about the
deleteriousness of nonsynonymous variants. Raw data can be found
at https://doi.org/10.17605/OSF.IO/7X8NG.
2.7. Quantitative real-time PCR (qRTPCR) and endpoint PCR
Total RNA was isolated from SUM44 cells or LCCTam cells
cultured in the absence of 4HT for 14 days, using TRIzol (Thermo-
Fisher) and the RNEasy Mini Kit (Qiagen). RNA was reverse tran-
scribed using the High Capacity cDNA Reverse Transcription kit
(ThermoFisher). Primers were synthesized by Integrated DNA
Technologies (Coralville, IA) and sequences are listed in Table 1.
qRTPCR was performed using Power SYBR Green PCR Master Mix
(ThermoFisher) in 384-well plates using the Applied Biosystems
7900HT Fast Real-Time PCR System. For each gene of interest, the
2DDct method described by Applied Biosystems (Life Technologies)
compared with the geometric mean of the Ct values for b-actin
(ACTB) and b-tubulin (TUBB) acting as housekeeping genes was
used to calculate relative expression.
2.8. Western blot
SUM44 and LCCTam cells were seeded in 6-well plastic tissue
culture plates at 250,000 cells/well 24e48 h prior to treatment
with the indicated concentrations of drug, or prior to lysis in the
case of untreated cells. Cell lysate preparation in modiﬁed RIPA
buffer, SDS-PAGE, and transfer to nitrocellulose membrane were
carried out as described previously (Heckler et al., 2014, 2016;Riggins et al., 2008). Membranes were blocked in 5% nonfat dry
milk in TBST buffer, then probed overnight with the following
primary antibodies: phospho-MAPK (1:500e1:1000) and total
MAPK (1:500e1:1000) from Cell Signaling (Danvers, MA);
phospho-Serine 118 ERalpha (1:500) from EMDMillipore (Billerica,
MA); and total ERalpha (clone 6F11, 1:500e1:1000) from Vector
Labs (Burlingame, CA). Incubation with horseradish peroxidase
(HRP)-conjugated secondary antibodies from GE Healthcare
(1:5000) and exposure to ﬁlm were performed as described pre-
viously (Heckler et al., 2014, 2016; Riggins et al., 2008). Membranes
were reprobed for beta-actin (Sigma Aldrich, 1:10,000) or GAPDH
(Santa Cruz Biotechnology, 1:5000) for 1 h at room temperature
as a loading control.2.9. Immunoﬂuorescence microscopy
SUM44 and LCCTam cells were seeded on poly-l-lysine (Sigma)
coated 18 mm diameter round coverslips in 24-well plastic tissue
culture plates at 80,000 cells/well. 48 h later, cells were ﬁxed in
3.2% paraformaldehyde for 5 min, washed with PBS, then per-
meabilized with 0.2% Triton X-100 for 5 min. Cells were incubated
with an anti-GRM1/mGluR1 primary antibody (Cell Signaling,
1:200) in antibody diluent (0.1% gelatin, 10% normal donkey serum
in PBS). Staining negative controls were incubated in antibody
diluent only. All coverslips were then co-incubated for 20 min with
AlexaFluor594-conjugated anti-rabbit secondary antibody (Life
Technologies, 1:200), DAPI (Life Technologies, 1:500), and Alexa-
Fluor488-conjugated phalloidin (Cytoskeleton, Denver, CO, 1:300).
Phalloidin was used to establish consistent focal planes across
samples for image capture, but not included in the ﬁnal image
stack. Stained cells were imaged on a Leica SP8 AOBSþþ laser
scanning confocal microscope in the LCCC Microscopy and Imaging
Shared Resource (MISR). Gain and exposure time were established
for LCCTam cells prior to imaging SUM44 and negative control
coverslips, changing only focus to acquire these images.2.10. Cell proliferation
SUM44 and LCCTam cells were seeded in 96-well plastic tissue
culture plates at 10,000 cells/well. MDA-MB-231 cells were seeded
at 1000 cells/well. 24e48 h later, cells were treated with the indi-
cated concentrations of 4HT, U0126, Riluzole (RIL), Fulvestrant (ICI),
or combinations thereof. For 4HT/U0126 experiments, SUM44 and
LCCTam cells were treated for 10 days while MDA-MB-231 cells
were treated for 6 days. For RIL/ICI experiments, SUM44 and
LCCTam cells were treated for 8 days. At the conclusion of each
experiment, cells were stained with a solution of 0.5% crystal violet
in 25%methanol. Once dry, the crystal violet stainwas resolubilized
with citrate buffer and a dual-wavelength absorbance measure-
ment was obtained from an ELx808 plate reader (BioTek, Winooski,
VT) in the LCCC Genomics and Epigenomics Shared Resource
(GESR) at 562 and 405 nm as previously described (Heckler et al.,
2016).
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Image compilation was performed using Adobe Photoshop
Creative Suite 5.1 (San Jose CA), and all statistical analyses other
than those discussed above for eomics assays were performed
using GraphPad Prism 6.0 or 7.0 (La Jolla CA). Venn diagrams were
generated using Venny 2.1 (http://bioinfogp.cnb.csic.es/tools/
venny/index.html). Statistical signiﬁcance is deﬁned as p  0.05,
with the following labeling convention: *p < 0.05; **p < 0.01;
***p < 0.001; and ****p < 0.0001. The details of each test performed
are shown in the relevant Figure Legends. In the survival analysis
including multiple genes the mean expression of the signature was
computed ﬁrst and the median of the mean was used as the ﬁnal
cutoff in the Cox regression analysis. Relative index (RI) calculations
were used to test the nature of the interaction between U0126 and
4HT, or Riluzole (RIL) and Fulvestrant (ICI) (Romanelli et al., 1998).
Brieﬂy, the R index is calculated as the expected cell survival (Sexp;
the product of relative survival in 4HT or ICI and relative survival in
U0126 or RIL) divided by the observed relative survival in the
presence of the combination (Sobs, 4HT þ U0126 or ICI þ RIL). Sexp/
Sobs ¼ 1.0 denotes an additive interaction, while >1.0 denotes a
synergistic interaction, though R index values approaching 2.0 are
indicative of more robust synergy (Romanelli et al., 1998).
3. Results and discussion
3.1. Relevance of ESRRG and the SUM44/LCCTam model system to
Luminal A ILC clinical specimens
We previously demonstrated that ERRg stimulates TAM-
resistance in the SUM44/LCCTam model of ILC (Riggins et al.,
2008), now characterized as belonging to the hormone related
(HR) ILC subtype (Michaut et al., 2016). Exogenous expression of
ESRRG was later shown to induce TAM-resistance in other, non-ILC
breast cancer models (Girard et al., 2015; Lü et al., 2015). ESRRG is
located at chromosome 1q41, which is more often ampliﬁed in ILC
vs. IDC (Desmedt et al., 2016; Gruel et al., 2010; Michaut et al.,
2016). Accordingly, ESRRG mRNA expression is signiﬁcantly higher
in primary Luminal A ILC vs. IDC tumors in both The Cancer
Genome Atlas (TCGA) (Fig. 1A) and METABRIC datasets (Fig. 1B). In
TCGA, ESRRG is among the top ~100 genes that discriminate ILC
from IDC. We recently published a signature of 37 validated tran-
scriptional target genes of ESRRG that is prognostic in TAM-treated
breast tumors irrespective of histologic subtype (Madhavan et al.,
2015), and show here that a 4-gene subset of this signature
(AHSA1, TIMM17A, TRRAP, SPTLC2) has better prognostic value in
Luminal A ILC (Fig. 1C) than Luminal A IDC (Supplementary Fig. 1A)
in the TCGA dataset. There is a similar trend in Luminal A ILC from
the METABRIC dataset, but it does not reach statistical signiﬁcance
(Fig. 1D, Supplementary Fig. 1B). These data support the relevance
of the SUM44/LCCTam model system as a platform to identify
additional alterations in gene expression, as well as copy number
and mutations, in ILC that are associated with poor response to
TAM.
3.2. Gene expression analysis identiﬁes differential transcriptome
response to 4HT in LCCTam cells
The LCCTam cell line was selected by growing cells in increasing
doses of 4HT, and thus microarray analysis of how SUM44 and
LCCTam cells respond to 4HT gives insight into what drives resis-
tance. We previously reported that, in conjunction with ESRRG,
aberrant activating protein 1 (AP1) activity plays a key functional
role in the TAM-resistant phenotype of LCCTam cells, and identiﬁed
candidate AP1-regulated genes whose expression is increased inLCCTam cells (Riggins et al., 2008). This was based on gene
expression microarray analysis comparing parental SUM44 cells
with LCCTam cells continually maintained in 500 nM 4HT
(GSE12708). To extend these ﬁndings and determine how 4HT
might differentially affect the transcriptome of SUM44 and LCCTam
cells, we performed additional gene expressionmicroarrays on RNA
extracted from SUM44 cells treated with 500 nM 4HT for 24 h, and
from LCCTam cells cultured in the absence of 4HT for 14 days.
Affymetrix U133A raw data from all four experimental conditions
(2 pre-existing, 2 new) were preprocessed together, and we iden-
tiﬁed genes with a fold change of 1.45 for each pairwise com-
parison with a univariate p value  0.05 (Fig. 2A). Speciﬁcally,
SUM44 cells treated with 4HT were compared with untreated cells,
and LCCTam grown in 4HT were compared with those removed
from 4HT. As anticipated, there are fewer overall changes in gene
expression in response to 4HT in LCCTam cells. The 1980 genes that
are differentially expressed in response to 4HT in both SUM44 and
LCCTam are largely regulated in the same direction, and presum-
ably represent genes that do not drive TAM-resistance, since their
induction or repression by 4HToccurs despite differences in growth
response between these two cell lines.
We then compared gene networks and pathways that are
altered in response to 4HT in sensitive (SUM44) and resistant
(LCCTam) cell lines using Ingenuity Pathway Analysis (IPA, Fig. 2B
and C and Supplementary Tables 2 and 3). The PI3K/AKT pathway is
differentially regulated in response to 4HT in SUM44 and LCCTam,
whereby “PI3K/AKT Signaling” is increased in LCCTam in the
presence of 4HT (Z score 0.7303) but decreased in SUM44 in the
presence of 4HT (Z score 0.8485). PIK3CA mutation is enriched in
Luminal A ILC (Ciriello et al., 2015) and a likely driver of ILC
endocrine resistance that could be targeted with PI3K inhibitors
(Bosch et al., 2015). Pharmacological inhibition of this pathway is
critical for overcoming endocrine resistance in long-term estrogen
deprived (LTED) models of AI resistance (Miller et al., 2010) and in
PTEN-knockdown breast cancer cells (Fu et al., 2014), though these
are all of IDC origin.
Changes in gene expression seen only in SUM44 in response to
4HT should represent changes that drive growth inhibition, as this
phenotype is not seen in LCCTam. “Aryl Hydrocarbon Receptor
(AHR) Signaling” is the 5th most enriched pathway in SUM44, but
the 26th for LCCTam. AHR signaling is repressed by 4HT in SUM44,
but induced in LCCTam. Normally, AHR signals the presence of
xenobiotics, but has also been implicated as important for organ-
ogenesis and the renewal of breast cancer stem-like cells (Bock and
K€ohle, 2006; Stanford et al., 2016). In an IDC xenograft model, TAM-
resistant tumors treated with an AHR antagonist and 4HT exhibit
decreased tumor growth compared with those treated with 4HT
alone, or non-resistant tumors treated with an AHR antagonist
(Dubrovska et al., 2012). Finally, signiﬁcant differences are observed
in components of the “Androgen Signaling” pathway. This pathway
is the 4th most regulated pathway for the LCCTam list while it is
89th for SUM44 cells. Increased androgen receptor (AR) signaling
can drive TAM-resistance in a model of IDC (De Amicis et al., 2010)
and women treated with TAM have increased risk for resistance if
their tumors have a high AR:ER protein expression ratio (Cochrane
et al., 2014). We have previously reported that ER mRNA and pro-
tein levels are reduced in LCCTam cells (Riggins et al., 2008), sug-
gesting that LCCTam cells may have a functional increase in the
AR:ER ratio that contributes to TAM resistance.
3.3. aCGH implicates MAPK1 ampliﬁcation and FOXA1 gain in
acquisition of TAM-resistance
Multiple studies have identiﬁed recurrent chromosomal am-
pliﬁcations, gains, losses, and deletions characteristic of ILC
Fig. 2. Response to 4HT differs in SUM44 and LCCTam and suggests targetable pathways of TAM-resistance. A, SUM44 cells were treated with 500 nM 4HT for 24 h and compared
with controls while LCCTam maintained in 500 nM 4HT were compared with cells that were not treated with 4HT for 2 weeks. Affymetrix probe IDs for each comparison that had a
fold change of 1.45 with a univariate p-value 0.05 were compared. B and C, Ingenuity Pathway Analysis (IPA) of Canonical Pathways for each cell line was completed and the top
20 affected pathways are shown; those discussed in the Results section are bolded. Red denotes pathways predicted to be downregulated in response to 4HT while green denotes
upregulation. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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array comparative genomic hybridization (aCGH) we conﬁrm that
the parental SUM44 cell line has many of these features, including
broad gain of chromosome 1q, losses on the p arm of chromosome
10 that encompass PTEN, and focal ampliﬁcation of ﬁbroblast
growth factor receptor 1 (FGFR1) and cyclin D1 (CCND1) (Fig. 3A and
(Forozan et al., 1999; Turner et al., 2010)). Whenwe ﬁrst established
the TAM-resistant variant of SUM44 (LCCTam), we reported that
there are no gross chromosomal rearrangements in LCCTam as
compared to SUM44 (Riggins et al., 2008). Here, we use aCGH to
more ﬁnely map focal alterations that have emerged in LCCTam
cells (Fig. 3B and C). Using two different global analysis methods
(CBS and ADM-2), we identify a chromosome 22 ampliﬁcation that
encompasses mitogen activated protein kinase 1 (MAPK1, also
known as extracellular signal regulated kinase 2 or ERK2) and a
chromosome 8 deletion that includes CCAAT/Enhancer Binding
Protein Delta (CEBPD). The ADM-2 method further identiﬁes a
chromosome 14 gain that includes the gene encoding forkhead boxA1 (FOXA1). All three of these genes have been previously impli-
cated in altered response to endocrine therapy or ER signaling in
ER þ breast cancer, while FOXA1 mutation is signiﬁcantly enriched
in Luminal A ILCs from TCGA (Ciriello et al., 2015; Fu et al., 2016;
Hurtado et al., 2011; Mendoza-Villanueva et al., 2016; Oyama
et al., 2011; Wright et al., 2014). FOXA1 is a pioneer factor known to
inﬂuence how ER and other steroid hormone receptors function (Fu
et al., 2016; Hurtado et al., 2011; Jozwik and Carroll, 2012),
including SUM44 cells, where FOXA1 motifs are highly enriched at
sites of ER chromatin binding in the presence and absence of 17b-
estradiol (Irish et al., 2016). It has been recently shown that FOXA1
is ampliﬁed in TAM-resistant MCF7 cells and copy-number gain
exists in 20% of TCGA breast tumors, especially in the Luminal B
subtype (Fu et al., 2016). We subsequently validated a statistically
signiﬁcant increase in MAPK1 and FOXA1 mRNA expression
(Fig. 3D), as well as elevated MAPK1 (ERK2) total protein and
activating phosphorylation (Fig. 3E), in the resistant LCCTam cells.
Use of an insertional mutational screen in mice with Cdh1
Fig. 3. MAPK1 ampliﬁcation and FOXA1 gain in TAM-resistant ILC cells. A, Copy number plot for parental SUM44 cell line. Log2 copy number (CN) ratios (Y axis) are shown as colored
points and the circular binary segmentation (CBS)-generated segments are shown as black lines. Gains and losses characteristic of ILC are shown. B, Copy number alterations in
LCCTam vs. SUM44 cells. Genes with the largest ampliﬁcation and deletion as determined by CBS are labeled as black squares. C, Table of selected chromosome locations, cytobands,
and genes showing signiﬁcant ampliﬁcation, gain, or deletion in LCCTam cells as determined by ADM-2. *denotes chromosome 14 gain identiﬁed only by ADM-2, whereas others
were identiﬁed by both CBS and ADM-2. D, Quantitative real-time polymerase chain reaction (RTPCR) validation of increased MAPK1 and FOXA1 mRNA expression in LCCTam cells.
Data are presented as relative expression calculated by the 2DDCt method and are the mean of 5 biological replicates ± standard deviation, with each biological replicate comprised
of 3 technical replicates. Data were analyzed by Mann-Whitney U test. E, Western blot analysis of phosphorylated and total ERK1/2 (MAPK1 gene ¼ ERK2 protein), phosphorylated
and total ER, and GAPDH as a loading control. LCCTam -4HT cells were cultured in the absence of 4HT for 48 h. Data shown are from a single representative experiment that was
performed independently twice. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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sary for ILC development in mouse models (Kas et al., 2017). Serine
118 of ER is a known substrate of ERK/MAPK signaling, and ER
phosphorylation at this site has been implicated in poor response to
TAM (Chen et al., 2013), though other studies contradict this (Kuske
et al., 2006; Murphy et al., 2004). Here, we show that ER phos-
phorylation at Serine 118 is markedly increased in the LCCTam
resistant variant, in the presence and absence of 4HT. Recently
developed LTED variants of ILC, which mimic resistance to AIs, also
have increased MAPK activity (Sikora et al., 2016), demonstrating
MAPK pathway deregulation in multiple, independent endocrine
resistant ILC models. PI3K and MAPK pathways overlap and require
a delicate balance for normal growth signaling (Aksamitiene et al.,
2012; Mendoza et al., 2011), and these pathways are both altered in
LCCTam. Further study of their functional interaction would be
helpful to determine treatment options targeting either or both.
This is also relevant clinically, since primary Luminal A ILC tumors
are enriched for PTEN loss and AKT activation as compared to IDC
(Ciriello et al., 2015).3.4. Whole-exome sequencing identiﬁes NF1 and multiple GRM/
mGluR mutations in acquired TAM-resistance
Mutations in CDH1 are a hallmark of ILC, while those affecting
PIK3CA and FOXA1 are overrepresented in Luminal A ILC vs. Luminal
A IDC. SUM44 cells have known loss of heterozygosity (LOH) and
mutation of CDH1 (van de et al., 2001), but aside from this and LOH/
mutation of TP53 (p53) (Wasielewski et al., 2006), the mutational
status of key drivers or breast cancer-associated genes in this ILC
cell line is not known. With respect to mutations that arise during
progression on endocrine therapy, multiple ESR1 (ER) mutations
are increasingly appreciated as drivers of clinical resistance to AIs,
and are also observed in a proportion of TAM- or Fulvestrant-
resistant disease (Chandarlapaty et al., 2016; Fribbens et al., 2016;
Gelsomino et al., 2016; Paoletti et al., 2016; Schiavon et al., 2015;
Spoerke et al., 2016; Wang et al., 2016). However, none of these
studies have speciﬁcally examined ILC.
We performed whole-exome sequencing (WES) analysis of
SUM44 and LCCTam cells to identify mutations that arise during
H. Stires et al. / Molecular and Cellular Endocrinology 471 (2018) 105e117112acquisition of TAM-resistance. Both the parental SUM44 and
resistant variant LCCTam containwild type ESR1, ERBB2 (HER2), and
FOXA1, and maintain their previously reported CDH1 and TP53
mutations (Supplementary Table 4). Comparison of LCCTam to
SUM44 cells identiﬁes one hundred eighty (180) unique predicted
protein- or splice site-altering mutations in one hundred ﬁfty two
(152) unique genes (Fig. 4A). The distribution of mutations is not
uniform, with chromosomes 16 and 17 having more and chromo-
somes 10 and 13 having fewer mutations per megabase (Mb) of
chromosome length than predicted. We focused on three speciﬁc
mutations (Fig. 4B). A splice-disrupting mutation is present in exon
43 of Neuroﬁbromin 1 (NF1), a tumor suppressor that is a key
negative regulator of the Ras/MAPK pathway, and while NF1 is
frequently mutated in sporadic breast cancers (Philpott et al., 2017),
its role in ILC is not fully understood. We conﬁrm that NF1mRNA is
expressed in both cell lines (Fig. 4C). Phenotypically, these data are
consistent with our aCGH, PCR, and Western blot results in Fig. 3Fig. 4. NF1 and multiple GRMs/mGluRs are mutated in TAM-resistant ILC cells. A, Distributio
were analyzed in relation to chromosome length in megabases (Mb) by linear regression a
denote chromosomes (numbers shown) with a greater than expected number of mutatio
chromosome locations, exons, alterations, and predicted functional consequences for genes
LCCTam cells. Data are presented as relative expression calculated by the 2DDCt method a
replicate comprised of 3 technical replicates. Data were analyzed by Mann-Whitney U test.
dataset, and the A229E mutation detected in LCCTam cells. Green denotes missense and blac
domain (green rectangle) and 7-pass transmembrane domain (7 Tm, blue rectangle) are s
nocytochemistry. Negative staining control ¼ no Ab (no primary antibody). Data shown are
Quantitative RTPCR validation of GRM2mRNA expression in LCCTam cells. Data are presented
replicates ± standard deviation, with each biological replicate comprised of 3 technical re
upregulated in LCCTam cells. Affymetrix gene expression microarray data are presented
replicates compared by unpaired t-test.(where we show that MAPK pathway activation is deregulated in
LCCTam cells) and with prior studies that implicate NF1 loss or
mutation with reduced efﬁcacy of endocrine therapy or poor
prognostic factors, respectively (Mendes-Pereira et al., 2012;
Uusitalo et al., 2017).
We further identify missense mutations in two members of the
GRM/mGluR family, GRM1 on chromosome 6 and GRM2 on chro-
mosome 3 (Fig. 4B). These members of the G-protein coupled re-
ceptor (GPCR) superfamily are key players in normal and pathologic
neurologic function, and there is a growing appreciation of their
contribution to cancer (Feigin, 2013). The GRM1 A229E and GRM2
I315V mutations found in LCCTam cells reside in the extracellular
glutamate binding regions of the receptors (Fig. 4D for GRM1). In
TCGA, GRM1 mutations occur at a greater frequency in primary
Luminal A ILC tumors (3%, Fig. 4D) than primary Luminal A IDC
tumors (0.5%, c2¼ 0.08), while GRM2mutations are not observed in
ILC. By ﬂuorescent immunocytochemistry, mGluR1/GRM1 proteinn of mutations in LCCTam cells by chromosome. Number of mutations per chromosome
nalysis. Dashed lines represent the 90%, 95%, and 99% conﬁdence intervals. Red points
ns, while green points denote those with fewer than expected. B, Table of selected
mutated in LCCTam cells. C, Quantitative RTPCR validation of NF1 mRNA expression in
nd are the mean of 5 biological replicates ± standard deviation, with each biological
D, Lollipop plot showing location of GRM1 mutations in Luminal A ILC from the TCGA
k denotes nonsense mutations. Positions of the extracellular ligand (glutamate) binding
hown. E, GRM1 protein expression in SUM44 and LCCTam cells by ﬂuorescent immu-
from a single representative experiment that was performed independently twice. F,
as relative expression calculated by the 2DDCt method and are the mean of 3 biological
plicates. Data were analyzed by Mann-Whitney U test. G, Multiple GRMs/mGluRs are
as mean fold change (increase) in LCCTam -4HT vs. SUM44 cells for three biological
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mRNA for GRM2 and ﬁve (5) other GRM family genes are increased
in LCCTam cells (Fig. 4F and G). There is precedent for a functional
interaction between GRM1, GRM2 and GRM4 and loss of CDH1, a
hallmark of ILC. (Telford et al., 2015) used a genome-wide small
inhibitory ribonucleic acid (siRNA) library in isogenic mammary
epithelial cells ewild type vs. CDH1-deleted e to identify synthetic
lethal vulnerabilities in cells lacking CDH1. The most enriched
functional category that preferentially inhibits CDH1-null cell
viability (when silenced) contains >200 genes that code for GPCR
signaling components, including these three GRMs/mGluRs. Finally,
high expression of GRM1, GRM2, or GRM4mRNA is each associated
with poor distant-metastasis free survival in women with
ER þ breast cancer treated with TAM, independent of lobular his-
tology ((Mehta et al., 2013) and Supplementary Fig. 2). However,
mechanistic studies of GRM/mGluR function in breast cancer have
largely focused on the triple negative or basal type (Banda et al.,
2014; Teh et al., 2015). Altogether these data suggest multiple
GRMs/mGluRs as potential players in TAM-resistant breast tumors,
including ILC.Fig. 5. The MEK inhibitor U0126 or the glutamate release inhibitor Riluzole enhances or re
phorylation. Cells were treated as indicated for 48 h prior to Western blot analysis for phosp
shown are from a single representative experiment. B, Crystal violet cell proliferation assays c
indicated concentrations of 4HT and/or U0126. Media were changed twice (SUM44, LCCTam
mean relative cell number ± standard deviation for 5e6 technical replicates from an indep
with post hoc Bonferroni correction. Relative index (RI) values ¼ 1 are additive, > 1 are syner
Fulvestrant (ICI), 10 mM Riluzole (RIL), or the combination (Combo). Media were changed on
technical replicates from an independent experiment performed three times. Data were ana
additive, > 1 are synergistic. D, Expression of ER protein in SUM44 and LCCTam cells follo
combination with 1 mM Fulvestrant (ICI), with b-actin as a loading control. Data shown are3.5. MEK or glutamate release inhibitors restore or enhance
endocrine response in SUM44/LCCTam cells
Hyperactivation of the MAPK/ERK cascade is a common feature
of endocrine resistance in ER þ breast cancer patients (Rugo et al.,
2016) and preclinical models (Creighton et al., 2006; Riggins et al.,
2007). Here, we identify NF1 mutation, MAPK1 ampliﬁcation and
upregulation, and increased MAPK substrate phosphorylation (ER
Serine 118) in TAM-resistant ILC cells. MAPK activity is also
increased in ILC-derived LTED cells, a model for resistance to AIs
(Sikora et al., 2016). Accordingly, U0126 e a potent and selective
MEK inhibitor chemical probe (Duncia et al., 1998) known to
enhance TAM responsiveness (Donovan et al., 2001; Kronblad et al.,
2005; Kurokawa et al., 2000) e suppresses MAPK/ERK phosphor-
ylation in ILC cells (Fig. 5A), and is additive or better-than-additive
in combination with TAM in suppressing the growth of responsive
(SUM44) or resistant (LCCTam) ILC cells, respectively (Fig. 5B).
U0126 does not confer TAM response to ER-negative MDA-MB-
231 cells (Fig. 5B), suggesting that interaction between MEK inhi-
bition and TAM requires ER.
The clinical efﬁcacy of MEK inhibitors is unfortunately quitestores endocrine response in ILC cells. A, MEK inhibitor U0126 suppresses ERK phos-
horylated ERK1/2 (MAPK1 gene ¼ ERK2 protein), and b-actin as a loading control. Data
onducted for 10 days (SUM44, LCCTam) or 6 days (MDA-MB-231) in the presence of the
) or once (MDA-MB-231) during the course of the experiment. Data are presented as
endent experiment performed at least twice. Data were analyzed by two-way ANOVA
gistic. C, Crystal violet proliferation assays conducted for 8 days in the presence of 1 mM
ce during the course of the experiment. Data are presented as mean % survival for 5e6
lyzed by two-way ANOVA with post hoc Tukey's test. Relative index (RI) values ¼ 1 are
wing 24 h treatment with the indicated concentrations of Riluzole (RIL) alone or in
from a single representative experiment performed independently three times.
H. Stires et al. / Molecular and Cellular Endocrinology 471 (2018) 105e117114variable, even in malignancies like non-small cell lung cancer and
melanoma where mutations in MAPK/ERK pathway components
are very common (Brant et al., 2017). These drugs also have
frequent dose-limiting toxicities. An attractive alternative to MEK
inhibition as a therapeutic strategy in ER þ ILC may be inhibition of
GRMs/mGluRs. Multiple GRMs upregulated in LCCTam cells
(Fig. 4G) are transducers of pro-proliferative glutamate signaling
(Feigin, 2013; Willard and Koochekpour, 2013; Yu et al., 2016), and
GRM1mutations can lead to hyperactivation of the MAPK pathway
in response to paracrine or autocrine glutamate (Esseltine et al.,
2013). Riluzole (Rilutek, RIL) is a broad-spectrum glutamate
release inhibitor that can inhibit paracrine or autocrine signaling
through multiple GRM family members (Abushahba et al., 2012;
Martino et al., 2013; Wen et al., 2014), and has preclinical efﬁcacy
in several different cancer models (Speyer et al., 2016; Teh et al.,
2015; Yu et al., 2016). We therefore tested RIL's ability to inhibit
ILC cell growth alone or in combinationwith endocrine therapy. RIL
has single agent growth-inhibitory activity and is signiﬁcantly
better than additive in combination with Fulvestrant (ICI), a se-
lective estrogen receptor degrader (SERD) in both cell lines
(Fig. 5C). RIL alone has no effect on ER expression, nor does it
modify downregulation of ER by ICI (Fig. 5D). Together these data
show that perturbation of two different actionable alterations
identiﬁed in this study (MAPK ampliﬁcation and hyperactivation,
GRM/mGluRmutation and upregulation) are effective against TAM-
resistant and responsive ILC cells. These data also provide (to our
knowledge) the ﬁrst preclinical proof of concept for the combina-
tion of RIL with endocrine therapy in ER þ breast cancer, and
speciﬁcally ILC.
4. Conclusions and future directions
A comprehensive analysis of genetic alterations in a preclinical
model of TAM-resistant ILC provides an opportunity to identify
novel pathways of resistance, ultimately leading to better treat-
ment options for patients. We completed Affymetrix gene expres-
sion arrays, Agilent aCGH, and Illumina WES on the parental
SUM44 and TAM-resistant LCCTam cell lines to gain insight into
similarities and differences in affected pathways across all three
platforms.
Analysis of AHR ChIPseq data shows enrichment of a consensus
FOXA1 binding motif in MCF7 cells (Lo and Matthews, 2012). FOXA1
mutation is a deﬁning feature of Luminal A ILC (Ciriello et al., 2015),
and in LCCTam cells we report FOXA1 gain and increased mRNA
expression, although its sequence is wild type based on our WES
data. Altogether, these data suggest that further study of the cross
talk between FOXA1 and AHR in this and other ILC models is war-
ranted. In prostate cancer, FOXA1 directs where AR binds in the
genome (Sahu et al., 2011; Wang et al., 2011), and in a TNBC AR-
positive cell line, AR binding sites almost completely overlap with
FOXA1 (Robinson et al., 2011). While AR signaling is predicted to be
upregulated in LCCTam, knowledge of how FOXA1 inﬂuences AR
signaling in ILC requires further study. Therapies targeting FOXA1
in breast cancer are in early stages of development, and may prove
useful in the treatment of ILC as theymature (Johnston et al., 2016).
Multiple alterations in copy number, sequence, and mRNA or
protein expression acquired by LCCTam cells impinge on theMAPK/
ERK signaling network, including MAPK1 ampliﬁcation, upregula-
tion, and hyperactivation, as well as NF1 mutation. Functional
validation further shows that MEK inhibition by U0126 improves or
restores TAM response in SUM44 and LCCTam cells. These data
suggest that MAPK deregulation is a core feature of the TAM
resistant phenotype of LCCTam cells, but we cannot rule out the
potential contributions of other alterations detected by aCGH and/
or WES. For example, LCCTam cells have acquired a frameshiftdeletion mutation in X-box binding protein 1 (XBP1, c.333delA,
K111fs). XBP1 is a known mediator of endocrine resistance (Davies
et al., 2008; Gomez et al., 2007; Hu et al., 2015) and, if translated,
this truncated XBP1 protein product would encode the ﬁrst 111
amino acids, which contain the region required for binding and
activating ER in the absence of estrogen (Ding et al., 2003).Whether
this mutant XBP1may contribute to TAM resistance in LCCTam cells
requires further study.
In the TCGA dataset GRM1 mutations are more prevalent in
primary Luminal A ILC than IDC, andmost somatic GRM1mutations
lead to hyperactivation of the MAPK pathway in response to
glutamate (Esseltine et al., 2013). Here, we show that multiple
members of the GRM/mGluR family are mutated and/or upregu-
lated at themRNA and protein level in LCCTam cells. Themost novel
ﬁnding of our study is that RIL, a broad-spectrum glutamate release
inhibitor that inhibits paracrine or autocrine signaling through
multiple GRM family members, has signiﬁcant single-agent and
combinatorial activity with ICI in TAM-responsive and eresistant
ILC cells. RIL's activity in other breast cancer models is not specif-
ically dependent upon GRM1, since silencing or overexpression of
GRM1 does not alter RIL-mediated growth inhibition (Speyer et al.,
2016). This is in contrast to RIL efﬁcacy in melanoma, which is
tightly associated with GRM1 expression. It may be that multiple
GRM/mGluR family members are required to transduce RIL's anti-
proliferative effect in breast cancer, an attractive idea given that
our data showmultiple GRMs/mGluRs are simultaneously mutated
and/or upregulated in TAM-resistant ILC cells. RIL is currently FDA
approved for slowing the progression of Amyotrophic Lateral
Sclerosis (ALS), and in Phase 1 clinical trials for melanoma
(NCT01303341). RIL is also the subject of a Phase 4 study testing its
ability to inhibit inﬂammation-associated fatigue and cognitive
dysfunction in breast cancer survivors by lowering levels of gluta-
mate in the central nervous system (NCT02796755). Our data
provide novel evidence supporting the rational combination of RIL
with endocrine agents, speciﬁcally in ILC where there already ap-
pears to be a GRM/mGluR dependency in the presence of CDH1 loss
(Telford et al., 2015). The extensive pre-existing clinical experience
with RIL in other disease settings makes repurposing this drug for
endocrine resistant, ER þ breast cancer, and in particular ILC, a
viable strategy to improve treatment outcomes in the near term.
There remains a lack of clear consensus whether patients with
ILC have a worse outcome than patients with IDC (Brouckaert et al.,
2014; Colleoni et al., 2012; Fritz et al., 2010; Pestalozzi et al., 2008).
What is clear is that IDC and ILC have distinct molecular signaling
and treatment regimens should consider these histologic subtypes
as distinct (Fritz et al., 2010; Weigelt et al., 2010). ILC tumors are
more commonly ERþ (Pestalozzi et al., 2008), historically sug-
gesting endocrine therapies should be beneﬁcial for these patients.
However, recent retrospective studies now show that patients with
ILC do not fare as well on TAM (Metzger Filho et al., 2015) or
exemestane (Strasser-Weippl et al., 2016) as compared to those
with IDC. Two ongoing prospective clinical trials seek to clarify
which endocrine therapy is most effective for ER þ ILC. The ﬁrst,
NCT02206984, is a neoadjuvant window trial comparing 21e24
days of Fulvestrant, TAM, or Anastrazole in women with ERþ,
HER2- ILC. The second, NCT02764541, is a perioperative study in
which the neoadjuvant phase will compare 15 days of Letrozole to
TAM in cohorts of women with either ER þ ILC or IDC; in the
adjuvant phase, womenwill continue on endocrine therapy with or
without the addition of the CDK4/6 inhibitor palbociclib. In each
study, the primary objective is to determine change in proliferation
(Ki67) pre- and post-neoadjuvant treatment, with secondary ob-
jectives that include assessments of ER, ER-regulated genes and
other measures with the goal of identifying markers of endocrine
response and resistance unique to ILC. Coupled with our preclinical
H. Stires et al. / Molecular and Cellular Endocrinology 471 (2018) 105e117 115models and those of others in the ﬁeld (Jambal et al., 2013; Sikora
et al., 2014, 2016), these efforts should identify a number of
actionable alterations that can be targeted to improve therapeutic
outcomes for women with ER þ ILC.
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